Fluids in Septic Shock (FISSH)
Key facts
- Who runs it
- McMaster University
- Where
- Canada and Saudi Arabia30 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 1,113 people enrolled
- Started
- 9 Sept 2018
- Ended
- 10 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- higher chloride crystalloid
- lower chloride crystalloid
- Record updated
- 27 February 2026
Who can take part
- Age
- 16 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- patients 16 years or greater who meet all of the following:
- require fluid resuscitation for refractory hypotension (systolic blood pressure <90 mmHg or mean arterial blood pressure<65 mmHg after 1 Litre bolus over 1 hour or less or organ hypo-perfusion (serum lactate >4 mmol/L)
- have a clinical suspicion of infection
- are within 6 hours of hospital admission or critical care response team consultation
- are anticipated to require ICU admission
Who cannot take part
- have previously enrolled in FISSH, or a confounding trial (e.g. a trial examining the effect of other intravenous fluids in septic shock patients)
- pre-established end stage renal disease (ESRD) or are receiving hemodialysis (intermittent or continuous) at time of enrolment, or
- intracranial bleed or intracranial hypertension during the index hospital admission
- bleeding/hemorrhage as likely cause of hypotension
- 10% of body surface area acute burn injury
- a lack of commitment to life support
- been transferred from another hospital or facility >6 hours since presentation to first hospital
- been admitted to ICU directly from the operating room or post anaesthetic care unit
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Despite evidence of the physiologic benefits and possible lower mortality associated with low chloride solutions, normal saline remains the most wildly used fluid in the world. Given uncertainty about the impact of lower chloride versus higher chloride solutions on mortality, it is unlikely that clinical practice will change without new and direct randomized controlled trial (RCT) evidence. Editorials published in leading critical care journals have called for RCT's to address this important clinical question. This trial will directly compare low chloride versus normal chloride for resuscitation in septic shock on patient-important outcomes such as mortality and AKI.
The 2 groups in the trial
- higher chloride solutionsExisting treatment, for comparison
higher chloride crystalloid (Normal saline - chloride concentration 154 mmol/L)
Treatment: higher chloride crystalloid
- lower chloride solutionsExisting treatment, for comparison
lower chloride crystalloid (Ringer's lactate - chloride concentration 110 mmol/L)
Treatment: lower chloride crystalloid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Fluids in Septic Shock (FISSH): a Randomized Controlled Trial
- Record updated
- 27 February 2026